We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMMT icon
51
CALL
Summit Therapeutics
SMMT
$10.4B
$2.13M 0.33%
100,000
– –
NAMS icon
52
NewAmsterdam Pharma
NAMS
$3.21B
$2.03M 0.31%
+112,359
New +$2.05M
DCTH icon
53
Delcath Systems
DCTH
$450M
$2.03M 0.31%
149,385
– –
AVR
54
Anteris Technologies
AVR
$806M
$2.01M 0.31%
531,515
-1,146,548
-68% -$4.66M
BPMC
55
DELISTED
Blueprint Medicines
BPMC
$1.92M 0.29%
+15,000
New +$1.56M
VKTX icon
56
Viking Therapeutics
VKTX
$3.8B
$1.8M 0.28%
67,813
+8,400
+14% +$221K
AKRO
57
DELISTED
Akero Therapeutics
AKRO
$1.77M 0.27%
33,143
-38,000
-53% -$1.73M
REGN icon
58
Regeneron Pharmaceuticals
REGN
$78.2B
$1.76M 0.27%
3,361
+2,000
+147% +$1.12M
RGNX icon
59
Regenxbio
RGNX
$638M
$1.71M 0.26%
207,818
-142,534
-41% -$1.19M
DVAX
60
DELISTED
Dynavax Technologies
DVAX
$1.69M 0.26%
170,000
– –
MLTX icon
61
MoonLake Immunotherapeutics
MLTX
$1.48B
$1.62M 0.25%
34,314
+28,890
+533% +$1.18M
ORKA
62
Oruka Therapeutics
ORKA
$5.72B
$1.6M 0.25%
142,780
+10,000
+8% +$104K
KNSA icon
63
Kiniksa Pharmaceuticals
KNSA
$5.73B
$1.56M 0.24%
56,540
+15,128
+37% +$385K
CRNX icon
64
Crinetics Pharmaceuticals
CRNX
$8.89B
$1.53M 0.23%
53,125
– –
TECX
65
Tectonic Therapeutic
TECX
$527M
$1.46M 0.22%
73,505
+10,902
+17% +$221K
SLNO
66
DELISTED
Soleno Therapeutics
SLNO
$1.45M 0.22%
17,330
-1,500
-8% -$112K
JANX icon
67
Janux Therapeutics
JANX
$973M
$1.43M 0.22%
62,088
-91,679
-60% -$2.42M
SRRK icon
68
Scholar Rock
SRRK
$5.49B
$1.41M 0.22%
39,677
-117,402
-75% -$3.69M
ATXS
69
DELISTED
Astria Therapeutics
ATXS
$1.34M 0.21%
249,646
-392,044
-61% -$1.9M
ALKS icon
70
Alkermes
ALKS
$8.31B
$1.29M 0.2%
+45,000
New +$1.34M
VIR icon
71
Vir Biotechnology
VIR
$1.5B
$1.26M 0.19%
250,000
– –
AGIO icon
72
Agios Pharmaceuticals
AGIO
$1.82B
$1.19M 0.18%
35,900
+8,000
+29% +$242K
CLDX icon
73
Celldex Therapeutics
CLDX
$2.96B
$1.17M 0.18%
57,466
+42,866
+294% +$834K
SWTX
74
DELISTED
SpringWorks Therapeutics
SWTX
$1.13M 0.17%
24,082
-183,696
-88% -$8.17M
ESTA icon
75
Establishment Labs
ESTA
$2.73B
$1.07M 0.16%
25,000
+17,000
+213% +$593K
1 2
3
4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.